HD Focus

Podes ganhar uma inscrição gratuita na Conferência EHA 2023 na Bélgica! A European Huntington Association e a International Huntington Association organizaram um concurso de fotografia durante o #MayAwarenessMonth2023 para uma nova e criativa maneira de aumentar a consciencialização para a Doença de Huntington. Falamos sempre da importância da comunidade global de DH e porque é …

Junta-te ao nosso Concurso de Fotografia “Juntos somos mais fortes!” Read More »

Hello from Dubrovnik, Croatia, where the 2023 CHDI Therapeutics Conference will be taking place from Monday, April 24th, through Thursday, April 27th!

This conference is a big one for HD researchers worldwide, from industry, academia, and nonprofit. Dozens of scientists will give talks on all things HD, from genetics, to therapeutics, to clinical trial news.

The HDBuzz Editorial team will be on the scene starting on the morning of Tuesday, April 24th, live-tweeting scientific talks and updates on the progress of clinical trials. Our Twitter updates are compiled below. Continue to follow live updates for the rest of the conference with the hashtag #HDTC2023.

For a summary of last year’s conference, start here: https://en.hdbuzz.net/320 We’ll post summaries in article format for each day of the conference.

Knowing what we need to know

Top line results of the PROOF-HD study, run by Prilenia Therapeutics and testing pridopidine, have been announced at the American Academy of Neurology convention. Sadly the trial outcome was negative. We recap the history of pridopidine in Huntington’s disease, review the trial results, and figure out where this disappointing result leaves us.

The drug: pridopidine

Pridopidine has been under investigation as a possible treatment for Huntington’s disease since the early 2000s and has a long and colourful history. It was initially developed by the Swedish company Neurosearch who called it Huntexil.

Neurosearch thought pridopidine was able to stabilise levels of dopamine, which is important for movement control. They hoped it might therefore suppress involuntary movements and improve voluntary movements. They ran two trials called MermaiHD and HART, but the drug did not show conclusive benefits for movement control.

In 2012, Teva Pharmaceuticals purchased the right to develop pridopidine, and ran a third study called PRIDE-HD which tested several different doses of pridopidine, again with the aim of improving movement function.

Postcard from Dubrovnik Jedes Jahr treffen sich Forscher auf dem Gebiet der Huntington-Krankheit mit Pharma- und Biotechnologieunternehmen auf der CHDI Therapeutics Conference, um Informationen und Ideen auszutauschen.  Die Postcards sind eine Reihe von kurzen Videos, die sich an Nicht-Wissenschaftler richten.  Sie vermitteln die wichtigsten Themen, wissenschaftlichen Durchbrüche und Neuigkeiten zu […]